{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:51:21Z","timestamp":1786402281997,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R335-2019-2020"],"award-info":[{"award-number":["R335-2019-2020"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The Philadelphia chromosome-negative myeloproliferative neoplasms are a group of slowly progressing haematological malignancies primarily characterised by an overproduction of myeloid blood cells. Patients are treated with various drugs, including the JAK1\/2 inhibitor ruxolitinib. Mathematical modelling can help propose and test hypotheses of how the treatment works.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We present an extension of the Cancitis model, which describes the development of myeloproliferative neoplasms and their interactions with inflammation, that explicitly models progenitor cells and can account for treatment with ruxolitinib through effects on the malignant stem cell response to cytokine signalling and the death rate of malignant progenitor cells. The model has been fitted to individual patients\u2019 data for the <jats:italic>JAK2<\/jats:italic> V617F variant allele frequency from the COMFORT-II and RESPONSE studies for patients who had substantial reductions (20 percentage points or 90% of the baseline value) in their <jats:italic>JAK2<\/jats:italic> V617F variant allele frequency (<jats:italic>n<\/jats:italic> = 24 in total).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The model fits very well to the patient data with an average root mean square error of 0.0249 (2.49%) when allowing ruxolitinib treatment to affect both malignant stem and progenitor cells. This average root mean square error is much lower than if allowing ruxolitinib treatment to affect only malignant stem or only malignant progenitor cells (average root mean square errors of 0.138 (13.8%) and 0.0874 (8.74%), respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Systematic simulation studies and fitting of the model to the patient data suggest that an initial reduction of the malignant cell burden followed by a monotonic increase can be recapitulated by the model assuming that ruxolitinib affects only the death rate of malignant progenitor cells. For patients exhibiting a long-term reduction of the malignant cells, the model predicts that ruxolitinib also affects stem cell parameters, such as the malignant stem cells\u2019 response to cytokine signalling.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1384509","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T04:29:49Z","timestamp":1715056189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms"],"prefix":"10.3389","volume":"15","author":[{"given":"Tobias Idor","family":"Boklund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Gudmand-Hoeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Kranker","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Alma","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Schjellerup","family":"Eickhardt-Dalb\u00f8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny T.","family":"Ottesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stiehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications","volume":"35","author":"Tremblay","year":"2021","journal-title":"Hematology\/Oncology Clinics North America"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017697","article-title":"JAK2V617F allele burden in polycythemia vera: burden of proof","volume":"141","author":"Moliterno","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPN","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nri1779","article-title":"Bone-marrow haematopoietic-stem-cell niches","volume":"6","author":"Wilson","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: A review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"B8","volume-title":"Ruxolitinib in the treatment of Myelofibrosis - Studies on Chronic Inflammation in Myelofibrosis and The Impact of JAK1-2 Inhibitor Treatment with Ruxolitinib upon Clinical and Biochemical Parameters with Particular Focus on Markers of Oxidative Stress","author":"Bj\u00f8rn","year":"2016"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1729-7","article-title":"The ruxolitinib effect: Understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J Trans Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0638-y","article-title":"Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations","volume":"34","author":"Austin","year":"2020","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558015","article-title":"JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082100","article-title":"Clonal hematopoiesis and mutations of myeloproliferative neoplasms","volume":"12","author":"Kj\u00e6r","year":"2020","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V51.5.941.941","article-title":"Unified hypothesis for the origin of aplastic anemia and periodic hematopoiesis","volume":"51","author":"Mackey","year":"1978","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(02)00832-9","article-title":"A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity","volume":"30","author":"Roeder","year":"2002","journal-title":"Exp Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00082","article-title":"Stem cell control, oscillations, and tissue regeneration in spatial and non-spatial models","volume":"3","author":"Rodriguez-Brenes","year":"2013","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005803","article-title":"Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments","volume":"13","author":"Ashcroft","year":"2017","journal-title":"PloS Comput Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/stmcls\/sxac079","article-title":"HSC niche dynamics in regeneration, pre-malignancy, and cancer: insights from mathematical modeling","volume":"41","author":"Pedersen","year":"2023","journal-title":"Stem Cells"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2006-0136","article-title":"Successful therapy must eradicate cancer stem cells","volume":"24","author":"Dingli","year":"2006","journal-title":"Stem Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071128","article-title":"A mathematical model of cancer stem cell driven tumor initiation: implications of niche size and loss of homeostatic regulatory mechanisms","volume":"8","author":"Gentry","year":"2013","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120374119","article-title":"Inferring the initiation and development of myeloproliferative neoplasms","volume":"119","author":"Hermange","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20140079","DOI":"10.1098\/rsif.2014.0079","article-title":"Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse","volume":"11","author":"Stiehl","year":"2014","journal-title":"J R Soc Interface"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-016-0154-1","article-title":"Emergence of heterogeneity in acute leukemias","volume":"11","author":"Stiehl","year":"2016","journal-title":"Biol Direct"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183620","article-title":"Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development","volume":"12","author":"Andersen","year":"2017","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jtbi.2017.05.012","article-title":"Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms","volume":"425","author":"Zhang","year":"2017","journal-title":"J Theor Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jtbi.2019.01.001","article-title":"Bridging blood cancers and inflammation: The reduced Cancitis model","volume":"465","author":"Ottesen","year":"2019","journal-title":"J Theor Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2508","article-title":"Cell division patterns in acute myeloid leukemia stem-like cells determine clinical course: A model to predict patient survival","volume":"75","author":"Stiehl","year":"2015","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0283","article-title":"Mathematical modeling provides evidence for niche competition in human AML and serves as a tool to improve risk stratification","volume":"80","author":"Stiehl","year":"2020","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082119","article-title":"Mathematical modeling of MPNs offers understanding and decision support for personalized treatment","volume":"12","author":"Ottesen","year":"2020","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2007.05.003","article-title":"Optimal control of treatment in a mathematical model of chronic myelogenous leukemia","volume":"210","author":"Nanda","year":"2007","journal-title":"Math Biosci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001561","article-title":"Optimizing IFN alpha therapy against Myeloproliferative Neoplasms","volume":"386","author":"Hermange","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.10.006","article-title":"Hematopoiesis in numbers","volume":"42","author":"Cosgrove","year":"2021","journal-title":"Trends Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0497-0","article-title":"Population dynamics of normal human blood inferred from somatic mutations","volume":"561","author":"Lee-Six","year":"2018","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2008.0143","article-title":"Modeling of asymmetric cell division in hematopoietic stem cells\u2014Regulation of self-renewal is essential for efficient repopulation","volume":"18","author":"Marciniak-Czochra","year":"2009","journal-title":"Stem Cells Dev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.coisb.2017.09.006","article-title":"Stem cell self-renewal in regeneration and cancer: Insights from mathematical modeling","volume":"5","author":"Stiehl","year":"2017","journal-title":"Curr Opin Syst Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.163584","article-title":"Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08","article-title":"The replication rate of human hematopoietic stem cells in vivo","volume":"117","author":"Catlin","year":"2011","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"New Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"New Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflammation"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000645","article-title":"New perspectives of interferon-alpha2 and inflammation in treating philadelphia-negative chronic myeloproliferative neoplasms","volume":"5","author":"Hasselbalch","year":"2021","journal-title":"HemaSphere"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v122.21.1591.1591","article-title":"Clinical resistance to ruxolitinib is more frequent in patients without MPN-associated mutations and is rarely due to mutations in the JAK2 kinase drug-binding domain","volume":"122","author":"Andreoli","year":"2013","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3570-8","article-title":"International external quality assurance of JAK2 V617F quantification","volume":"98","author":"Asp","year":"2019","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384509\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T07:46:05Z","timestamp":1716450365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384509\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2024.1384509"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1384509","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"article-number":"1384509"}}